1,019 results match your criteria Blood Reviews[Journal]


Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues.

Blood Rev 2019 Apr 17. Epub 2019 Apr 17.

CNRS, IGDR (Institut de Génétique et Développement de Rennes), Univ Rennes, UMR 6290, Rennes F-35000, France; Pediatric Hematology Department, University Hospital, Rennes, France. Electronic address:

Long-term survival rates in childhood acute lymphoblastic leukemia (ALL) are currently above 85% due to huge improvements in treatment. However, 15-20% of children still experience relapses. Relapses can either occur in the bone marrow or at extramedullary sites, such as gonads or the central nervous system (CNS), formerly referred to as ALL-blast sanctuaries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.04.003DOI Listing

Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs.

Authors:
Alan T Nurden

Blood Rev 2019 Mar 20. Epub 2019 Mar 20.

Institut de Rhythmologie et de Modélisation Cardiaque, Plateforme Technologique d'Innovation Biomédicale, Hôpital Xavier Arnozan, Pessac, France. Electronic address:

In contrast to the inherited platelet disorder given by mutations in the ITGA2B and ITGB3 genes, mucocutaneous bleeding from a spontaneous inhibition of normally expressed αIIbβ3 characterizes acquired Glanzmann thrombasthenia (GT). Classically, it is associated with autoantibodies or paraproteins that block platelet aggregation without causing a fall in platelet count. However, inhibitory antibodies to αIIbβ3 are widely associated with primary immune thrombocytopenia (ITP), occur in secondary ITP associated with leukemia and related disorders, solid cancers and myeloma, other autoimmune diseases, following organ transplantation while cytoplasmic dysregulation of αIIbβ3 function features in myeloproliferative and myelodysplastic syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.03.004DOI Listing

Extramedullary disease in multiple myeloma - controversies and future directions.

Blood Rev 2019 Apr 13. Epub 2019 Apr 13.

Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic. Electronic address:

Extramedullary disease of multiple myeloma (EM) remains a treatment challenge even in the era of new drugs. While many reports analyzing various aspects of EM have been published, mechanism of EM development has not been clarified yet. This review summarizes current knowledge about this clinical entity, including its history, diagnostics, imaging methods, incidence, prognosis, current treatment options, risk factors and known molecular mechanisms that might be involved in pathogenesis of EM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.04.002DOI Listing

Eosinophilia in acute myeloid leukemia: Overlooked and underexamined.

Blood Rev 2019 Mar 30. Epub 2019 Mar 30.

Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA. Electronic address:

The presence of eosinophilia in acute myeloid leukemia (AML) suggests an underlying core binding factor (CBF) lesion, a platelet derived growth factor (PDGFR) translocation, or another rare translocation (such as ETV6-ABL1). Each of these cytogenetic entities carries unique diagnostic, prognostic, and therapeutic implications. CBF AML is most common and as such, its treatment is more clearly established, consisting of intensive induction chemotherapy followed by cytarabine based consolidation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.03.007DOI Listing

Recent landmark studies in follicular lymphoma.

Blood Rev 2019 05 23;35:68-80. Epub 2019 Mar 23.

Department of Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain.

Follicular lymphoma (FL) is the most common indolent lymphoma. Therapeutic advances in the past decade have improved its prognosis, but some questions remain open, particularly over adapting therapy to each individual patient's disease risk. Several trials and large studies dealing with biological and therapeutic aspects of FL have been published in the past few months and may have immediate or near-future practice-changing implications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.03.006DOI Listing
May 2019
2 Reads

Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology.

Blood Rev 2019 05 25;35:59-67. Epub 2019 Mar 25.

Department of Thrombosis and Haemostasis, Leiden University Medical Centre, the Netherlands.

An increasing body of evidence suggests an association between cancer and atrial fibrillation (AF). The exact magnitude and underlying mechanism of this association are however unclear. Cancer-related inflammation, anti-cancer treatment and other cancer-related comorbidities are proposed to affect atrial remodelling, increasing the susceptibility of cancer patients for developing AF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.03.005DOI Listing
May 2019
2 Reads

Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.

Blood Rev 2019 05 3;35:43-50. Epub 2019 Mar 3.

Georgetown University Medical Center, Washington, DC, USA.

Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as the standard of care for management of people with haemophilia A. It is effective for treatment of bleeding events, as prophylaxis to prevent bleeding events and preserve joint function, and to support surgery in people with haemophilia A. Despite long experience in treating haemophilia A, we are only beginning to understand the functions of FVIII beyond its established role as a coenzyme to factor IXa to expedite thrombin generation through the intrinsic pathway of coagulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.03.002DOI Listing
May 2019
2 Reads

Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments.

Blood Rev 2019 05 14;35:51-58. Epub 2019 Mar 14.

Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

Blood pressure levels are directly associated with cardiovascular and cerebrovascular morbidity and mortality, rendering arterial hypertension a major public health problem affecting almost 1 billion people worldwide. Several models have been used for cardiovascular risk prediction based on traditional cardiovascular risk factors. Among them, hypertension represents a factor that may be triggered by distinct pathogenetic mechanisms in specific disease populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.03.003DOI Listing
May 2019
2 Reads
5.565 Impact Factor

Sickle cell retinopathy: What we now understand using optical coherence tomography angiography. A systematic review.

Blood Rev 2019 05 4;35:32-42. Epub 2019 Mar 4.

Postgraduate course, Bahiana School of Medicine and Public Health, Av. Dom João VI, 275, Brotas, 40290-000 Salvador, BA, Brazil.

For over four decades, efforts have been underway for the evaluation of sickle cell retinopathy (SCR) in an attempt to identify peripheral high-risk vascular abnormalities based on Goldberg's classification (gold-standard) (1971). The macula is an area in the center of the retina that is responsible for high-resolution central vision and is also affected in SCR. With the development of new technologies for retinal imaging, the macula became a main focus of interest in the study of sickle cell disease (SCD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.03.001DOI Listing
May 2019
1 Read
5.565 Impact Factor

Cellular immunotherapy for acute myeloid leukemia: How specific should it be?

Blood Rev 2019 05 23;35:18-31. Epub 2019 Feb 23.

Toronto General Research Institute, University Health Network, 2-207 101 College St., Toronto, Ontario M5G 1L7, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Significant improvements in the survival of patients with hematological cancers following hematopoietic stem cell transplantation provide evidence supporting the potency of immune cell-mediated anti-leukemic effects. Studies focusing on immune cell-based cancer therapies have made significant breakthroughs in the last few years. Adoptive cellular therapy (ACT), and chimeric antigen receptor (CAR) T cell therapy, in particular, has significantly increased the survival of patients with B cell acute lymphoblastic leukemia and aggressive B cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.02.001DOI Listing
May 2019
2 Reads

Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Blood Rev 2019 05 28;35:7-17. Epub 2019 Jan 28.

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

An alternative to human red blood cells (RBCs) for clinical transfusion would be advantageous, particularly in situations of massive acute blood loss (where availability and compatibility are limited) or chronic hematologic diseases requiring frequent transfusions (resulting in alloimmunization). Ideally, any alternative must be neither immunogenic nor pathogenic, but readily available, inexpensive, and physiologically effective. Pig RBCs (pRBCs) provide a promising alternative due to their several similarities with human RBCs, and our increasing ability to genetically-modify pigs to reduce cellular immunogenicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467751PMC
May 2019
5 Reads

Radiosynovectomy in haemophilia.

Blood Rev 2019 05 25;35:1-6. Epub 2019 Jan 25.

Department of Orthopaedic Surgery, "La Paz" University Hospital-IdiPaz, Paseo de la Castellana 261, 28046 Madrid, Spain. Electronic address:

Radiosynovectomy (RS) is a simple, effective and safe procedure for the control of haemophilic synovitis that causes repetitive haemarthrosis. It must be done after confirming clinically (hard and painless mass on palpation) and by ultrasonography the existence of synovitis in a joint with recurrent haemarthrosis. RS should be the first invasive option (instead of arthroscopic synovectomy) for treatment of chronic synovitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.01.002DOI Listing

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.

Blood Rev 2019 03 9;34:84-94. Epub 2019 Jan 9.

Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.

The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes of patients, but in parallel has changed the frequency and epidemiology of infections. Hence, the great strides in the indications and use of new active treatments for MM need parallel progresses on the best approach to prophylaxis and supportive therapy for infections. Moving from the recognition that the above issue represents an unmet clinical need in MM, an expert panel assessed the scientific literature and composed a framework of recommendations for optimal infection control in patients candidate to active treatment for MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.01.001DOI Listing
March 2019
3 Reads

Modelling human haemoglobin switching.

Blood Rev 2019 01 15;33:11-23. Epub 2018 Jun 15.

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia. Electronic address:

Genetic lesions of the β-globin gene result in haemoglobinopathies such as β-thalassemia and sickle cell disease. To discover and test new molecular medicines for β-haemoglobinopathies, cell-based and animal models are now being widely utilised. However, multiple in vitro and in vivo models are required due to the complex structure and regulatory mechanisms of the human globin gene locus, subtle species-specific differences in blood cell development, and the influence of epigenetic factors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183001
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.06.001DOI Listing
January 2019
16 Reads

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

Blood Rev 2019 03 5;34:67-83. Epub 2018 Dec 5.

Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA. Electronic address:

Immunotherapy has revolutionized therapy in both solid and liquid malignancies. The ability to cure acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with an allogeneic hematopoietic stem cell transplant (HSCT) is proof of concept for the application of immunotherapy in AML and MDS. However, outside of HSCT, only the anti-CD33 antibody drug conjugate gemtuzumab ozogamicin is currently approved as an antibody-targeted therapy for AML. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183007
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.12.001DOI Listing
March 2019
13 Reads

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.

Blood Rev 2019 03 14;34:45-55. Epub 2018 Nov 14.

Experimental Transplantation and Immunology Branch, National Cancer Institute, Building 10, Suite 3-3330, Bethesda, MD 20892, United States. Electronic address:

Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.11.002DOI Listing
March 2019
4 Reads

The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.

Blood Rev 2019 03 23;34:56-66. Epub 2018 Nov 23.

Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Brno, Czech Republic. Electronic address:

Multiple myeloma, which ranks as the second most common hematological malignancy, is known for its great genetic heterogeneity. One pathway, however, stands out in this diverse group. NF-κB pathway is one of the most important pathways in multiple myeloma not only for its role in pathogenesis, but also for its importance in various treatment strategies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183004
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.11.003DOI Listing
March 2019
8 Reads

Allogeneic hematopoietic cell transplantation; the current renaissance.

Blood Rev 2019 03 8;34:34-44. Epub 2018 Nov 8.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Allogeneic hematopoietic cell transplantation (HCT) provides the best chance for cure for many patients with malignant and nonmalignant hematologic disorders. Recent advances in selecting candidates and determining risk, procedure safety, utilization in older patients, use of alternative donors, and new or novel application of anti-cancer, immunosuppressive and antimicrobial agents have improved outcomes and expanded the role of HCT in hematologic disorders. Relapse remains the predominant cause of failure but enlightened use of new targeted and immunotherapeutic agents in combination with HCT promises to reduce relapse and further improve HCT outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.11.001DOI Listing
March 2019
20 Reads

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

Blood Rev 2019 03 28;34:16-25. Epub 2018 Oct 28.

Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy.

The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have improved patients' outcomes; however, at the same time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature and composed a framework of the best recommendations for optimal infection control in patient candidates to receive active treatment for myelodysplastic syndromes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183006
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.10.002DOI Listing
March 2019
14 Reads

Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.

Blood Rev 2019 03 1;34:26-33. Epub 2018 Nov 1.

Department of Hematology, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. Low CLEC12A expression on leukemic blasts seems to be independently associated with lower likelihood of achieving complete remission after 1 cycle of induction chemotherapy, shorter event free survival, as well as overall survival, indicating potential prognostic properties of CLEC12A expression itself. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183007
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.10.003DOI Listing
March 2019
16 Reads

Temporary Removal: Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review.

Blood Rev 2018 Oct 9. Epub 2018 Oct 9.

Academic Medical Center, Emma Children's Hospital, department of pediatric hematology, Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183007
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.10.001DOI Listing
October 2018
10 Reads

Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.

Blood Rev 2019 03 21;34:1-15. Epub 2018 Sep 21.

Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, USA; Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, USA.

Myelodysplastic syndromes (MDS) consist of a heterogeneous group of myeloid neoplasms characterized by inefficient hematopoiesis, variable cytopenias and a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS has been hampered by evolving diagnostic criteria and delayed classification of MDS as cancers until 2001. The poorly-understood nature of these neoplasms combined with the lack of effective therapies for decades contributed to suboptimal case ascertainment and underreporting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.09.001DOI Listing
March 2019
14 Reads

Venous thromboembolism incidence in hematologic malignancies.

Blood Rev 2019 01 21;33:24-32. Epub 2018 Jun 21.

Division of Hematology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

Venous thromboembolism (VTE) remains a major cause of morbidity and mortality in patients with cancer. Although some very well validated scores delineate the risk of VTE by cancer subtype and other risk factors, hematologic malignancies are underrepresented in these models. This subgroup represents a unique entity that undergoes therapy that can be thrombogenic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.06.002DOI Listing
January 2019
3 Reads

Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status.

Blood Rev 2019 01 20;33:106-116. Epub 2018 Aug 20.

Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli "Federico II", Naples, Italy. Electronic address:

Haemophilia is marked by joint bleeding (haemarthrosis) leading to cartilage damage (arthropathy). Lifelong prophylaxis-initiated after the first bleeding episode-leads to a dramatic decrease in arthropathy in haemophilia patients. However, adherence to continuous intravenous administrations of factor VIII (FVIII) or FIX products is challenging, and patients potentially suffer from breakthrough bleedings while on prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.08.003DOI Listing
January 2019
3 Reads

The emerging story of acute lymphoblastic leukemia among the Latin American population - biological and clinical implications.

Blood Rev 2019 01 14;33:98-105. Epub 2018 Aug 14.

University of Southern California, Los Angeles, CA, USA.

Higher incidence rates and poor outcomes have been reported among Latin American patients (Latinos) with acute lymphoblastic leukemia (ALL). Distinct patterns in recent genomic studies allude to a predisposing genetic component. In this review, we critically examine the increasing amount of empirical information on the epidemiology, outcomes and genomics of Latinos with ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.08.002DOI Listing
January 2019
19 Reads

Everything the clinician needs to know about evidence-based anticoagulation in pregnancy.

Blood Rev 2019 01 6;33:82-97. Epub 2018 Aug 6.

Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. Electronic address:

Pregnancy is a hemostatic challenge: women are prone to thromboembolism during their pregnancy and at the same time, especially during delivery, there is substantial risk of bleeding. Pregnant women are often excluded from randomized controlled trials, and high quality evidence regarding optimal anticoagulant management is thus lacking. Anticoagulants are being used in pregnancy for prevention and treatment of various pregnancy complications such as thrombotic events, preeclampsia and pregnancy loss. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183002
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.08.001DOI Listing
January 2019
45 Reads

Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care.

Blood Rev 2019 01 25;33:63-73. Epub 2018 Jul 25.

Division of Adult Hematology & Stem Cell Transplantation, Oncology Center, King Faisal Specialist Hospital and Research Center, s, Saudi Arabia; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address:

Recent advancements in cancer care, coupled with early detection and an aging population have resulted in significant growth of cancer survivors. Long term follow up of such survivors is essential given the heightened risk for development of late effects such as secondary neoplasms, cardiovascular disease or psychosocial dysfunction among others. As more patients with hematologic malignancies are cured or managed over protracted periods of time, awareness of such issues is paramount for the practicing clinicians for optimal patient management. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X183003
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.07.003DOI Listing
January 2019
6 Reads

Current and evolving understanding of atypical chronic myeloid leukemia.

Blood Rev 2019 01 29;33:74-81. Epub 2018 Jul 29.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Lev Place, Box 1079, New York, NY 10029, USA. Electronic address:

Atypical chronic myeloid leukemia (aCML) is a BCR-ABL1 negative myelodysplastic (MDS)/myeloproliferative (MPN) neoplasm with poor overall survival. The current 2016 WHO classification of myeloid neoplasms allows clinicians to more accurately differentiate aCML from its similar MDS/MPN overlap and MPN counterparts. In addition, the advent of next-generation sequencing has expanded our understanding of the molecular pathogenesis of aCML and its therapeutic potential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.07.004DOI Listing
January 2019
1 Read

Plasma contact factors as therapeutic targets.

Blood Rev 2018 11 12;32(6):433-448. Epub 2018 Apr 12.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address:

Direct oral anticoagulants (DOACs) are small molecule inhibitors of the coagulation proteases thrombin and factor Xa that demonstrate comparable efficacy to warfarin for several common indications, while causing less serious bleeding. However, because their targets are required for the normal host-response to bleeding (hemostasis), DOACs are associated with therapy-induced bleeding that limits their use in certain patient populations and clinical situations. The plasma contact factors (factor XII, factor XI, and prekallikrein) initiate blood coagulation in the activated partial thromboplastin time assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185818PMC
November 2018
1 Read

Are low-molecular-weight heparins safe and effective in children? A systematic review.

Blood Rev 2019 01 28;33:33-42. Epub 2018 Jun 28.

Department of Pediatric Hematology, ErasmusMC Sophia Children's Hospital, Rotterdam, the Netherlands.

The incidence of venous thromboembolism (VTE) in children is rising. Hence, there is an increasing off-label use of low-molecular-weight heparin (LMWH). There is little data about therapeutic and prophylactic LWMH dosages, and their safety and efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.06.003DOI Listing
January 2019
1 Read

Effect of the ABO blood group on susceptibility to severe malaria: A systematic review and meta-analysis.

Blood Rev 2019 01 17;33:53-62. Epub 2018 Jul 17.

Department of Epidemiology, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, USA; Public Health Research Institute of India, Mysore, India. Electronic address:

Understanding how ABO blood group interacts with Plasmodium falciparum (P. falciparum) infection may facilitate development of antimalarial treatments and vaccines. This study systematically summarizes information on the relationship of ABO blood group with severe P. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X173012
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.07.002DOI Listing
January 2019
13 Reads
5.565 Impact Factor

Rationale for assessing the therapeutic potential of resveratrol in hematological malignancies.

Blood Rev 2019 01 5;33:43-52. Epub 2018 Jul 5.

Department of Internal Medicine, Division of Hematology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan.

Promising results from pre-clinical studies on the naturally-occurring polyphenol resveratrol have generated considerable interest and somewhat excessive expectations regarding the therapeutic potential of this compound for treating or preventing various diseases, including cardiovascular and neurodegenerative disorders and cancer. Resveratrol has potent inhibitory activity in vitro against various tumor types, including cell lines derived from virtually all blood malignancies. Pharmacological studies have shown that resveratrol is safe for humans but has poor bioavailability, due to its extensive hepatic metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.07.001DOI Listing
January 2019
7 Reads

The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A.

Authors:
Gary E Gilbert

Blood Rev 2019 01 24;33:1-5. Epub 2018 May 24.

VA Boston Healthcare System, Harvard Medical School, Boston, MA, United States. Electronic address:

Hemophilia A is caused by decreased or dysfunctional blood coagulation factor VIII (FVIII). Recent developments in the understanding of FVIII biology, in particular the nature of FVIII binding sites on platelets, may provide new insight into the limitations of current assays. Recent data suggest that the phospholipid vesicles, which represent nonphysiologic membranes of high phosphatidylserine (PS) content, poorly reflect functional FVIII binding sites critical to coagulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.05.001DOI Listing
January 2019
2 Reads

Increased bone resorption in hemophilia.

Blood Rev 2019 01 25;33:6-10. Epub 2018 May 25.

Rush University, 1653 West Congress Parkway, Chicago, IL 60026, USA.

In patients with hemophilia, osteoporosis is frequently observed for which the etiology remains unclear. The aim of this paper is to review the available experimental evidence indicating the presence of this disorder in patients with hemophilia, explore the potential mechanisms which may lead to reduced bone mineral density (BMD) and speculate on useful interventions to circumvent it. A narrative review of the English literature up to April 2018 was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.05.002DOI Listing
January 2019

Current status and trends in the diagnostics of AML and MDS.

Blood Rev 2018 11 27;32(6):508-519. Epub 2018 Apr 27.

University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland. Electronic address:

Diagnostics of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have recently been experiencing extensive modifications regarding the incorporation of next-generation sequencing (NGS) strategies into established diagnostic algorithms, classification and risk stratification systems, and minimal residual disease (MRD) detection. Considering the increasing arsenal of targeted therapies (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.04.008DOI Listing
November 2018
5 Reads

Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.

Blood Rev 2018 11 14;32(6):480-489. Epub 2018 Apr 14.

Department of Medicine, Division of Hematology, Oncology, Arizona Cancer Center, The University of Arizona, Tucson, AZ, USA. Electronic address:

Hematological malignancies express high levels of CD47 as a mechanism of immune evasion. CD47-SIRPα triggers a cascade of events that inhibit phagocytosis. Preclinical research supports several models of antibody-mediated blockade of CD47-SIRPα resulting in cell death signaling, phagocytosis of cells bearing stress signals, and priming of tumor-specific T cell responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186508PMC
November 2018
49 Reads

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.

Blood Rev 2018 11 23;32(6):499-507. Epub 2018 Apr 23.

Department of Infectious Diseases, Peter MacCallum Cancer Centre, Victoria, Australia; National Centre for Infections in Cancer, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia; Department of Medicine, University of Melbourne, Victoria, Australia. Electronic address:

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia with infections a leading cause of morbidity and mortality. Recently there has been a paradigm shift from the use of chemo-immunotherapies to agents targeting specific B-lymphocyte pathways. These agents include ibrutinib, idelalisib and venetoclax. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X173015
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.04.007DOI Listing
November 2018
9 Reads

Time to repeal and replace response criteria for acute myeloid leukemia?

Blood Rev 2018 09 27;32(5):416-425. Epub 2018 Mar 27.

The Alfred Hospital and Monash University, Melbourne, Australia. Electronic address:

The International Working Group (IWG) response criteria for acute myeloid leukemia, published in 2003, have remained the standard by which the efficacy of new drugs is measured in clinical trials. Over the last decade, concepts related to treatment response have been challenged by several factors; for example, the dissociation between early clinical response and survival outcome in older patients, the recognition that epigenetic and newer differentiating-agent therapies may produce delayed responses and also hematologic improvement/transfusion independence without a morphologic response, and evidence that remissions without minimal (or measurable) residual disease (MRD) may result in outcomes superior to those of morphologic remissions with persistent MRD. The evolving role of MRD status as a potential surrogate for predicting long-term survival has enhanced the clinical need to standardize and incorporate emerging technologies that enable deeper responses beyond those recognized by the IWG, and to pre-emptively identify patients at risk of early relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.006DOI Listing
September 2018
2 Reads

T-cell acute lymphoblastic leukemia from miRNA perspective: Basic concepts, experimental approaches, and potential biomarkers.

Blood Rev 2018 11 12;32(6):457-472. Epub 2018 Apr 12.

Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland. Electronic address:

T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive and heterogeneous malignancy originating from T-cell precursors. The mechanisms of T-ALL pathogenesis related to non-protein coding part of the genome are currently intensively studied. miRNAs are short, non-coding molecules acting as negative regulators of gene expression which shape phenotype of cells in a complex and context-specific manner. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X173015
Publisher Site
http://dx.doi.org/10.1016/j.blre.2018.04.003DOI Listing
November 2018
9 Reads

Iron toxicity - Its effect on the bone marrow.

Blood Rev 2018 11 13;32(6):473-479. Epub 2018 Apr 13.

Independent Clinical Iron Expert, Via E.L.Cerva 200, 00143 Roma, Italy.

Excess iron can be extremely toxic for the body and may cause organ damage in the absence of iron chelation therapy. Preclinical studies on the role of free iron on bone marrow function have shown that iron toxicity leads to the accumulation of reactive oxygen species, affects the expression of genes coding for proteins that regulate hematopoiesis, and disrupts hematopoiesis. These effects could be partially attenuated by iron-chelation treatment with deferasirox, suggesting iron toxicity may have a negative impact on the hematopoietic microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.04.004DOI Listing
November 2018
27 Reads

Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly.

Blood Rev 2018 11 19;32(6):490-498. Epub 2018 Apr 19.

KU Leuven - University of Leuven, Department of Oncology, Laboratory for Experimental Hematology, University Hospitals Leuven, Department of Hematology, B-3000 Leuven, Belgium. Electronic address:

Lymphomas cause significant morbidity and mortality worldwide. A substantial number of patients ultimately relapse after standard treatment. However, the efficacy of these therapies can be counteracted by the patients' immune system, more specifically by myeloid-derived suppressor cells (MDSC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.04.006DOI Listing
November 2018
42 Reads

Recipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango.

Blood Rev 2018 11 12;32(6):449-456. Epub 2018 Apr 12.

Department of Microbiology and Immunology, Laboratory of Experimental Transplantation, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Department of Nephrology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address:

Allogeneic hematopoietic stem cell transplantation (alloHSCT) produces -similar to the long-established graft-versus-leukemia effect- graft-versus-solid-tumor effects. Clinical trials reported response rates of up to 53%, occurring mostly but not invariably in association with full donor chimerism and/or graft-versus-host disease. Although donor-derived T cells are considered the principal effectors of anti-tumor immunity after alloHSCT or donor leukocyte infusion (DLI), growing evidence indicate that recipient-derived immune cells may also contribute. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.04.002DOI Listing
November 2018
5 Reads

The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy.

Blood Rev 2018 09 30;32(5):426-432. Epub 2018 Mar 30.

Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, USA. Electronic address:

The JAK2V617F-positive myeloproliferative neoplasms (MPN) serve as an excellent model for the study of genomic instability accumulation during cancer progression. Recent studies highlight the implication of JAK2 activating mutations in the development of DNA damage via reactive oxygen species (ROS) production, replication stress induction and the accumulation of genomic instability via the increased degradation of p53 and acquisition of a "mutagenic" phenotype. The accumulation of genomic instability and acquisition of mutations in critical DNA damage repair (DDR) mediators appears to be implicated in the progression of JAK2V617F-positive MPN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.007DOI Listing
September 2018

Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI.

Blood Rev 2018 09 26;32(5):400-415. Epub 2018 Mar 26.

Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Heidelberg, Australia; University of Melbourne, Melbourne, Australia; Eastern Health, Box Hill, Australia. Electronic address:

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes. Despite the majority of patients being cured with combination chemoimmunotherapy, up to 30% eventually succumb to the disease. Until recently, baseline prognostic assessment has centred on the International Prognostic Index (IPI), although this index is yet to impact strongly on treatment choice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.005DOI Listing
September 2018
1 Read

To chelate or not to chelate in MDS: That is the question!

Blood Rev 2018 09 8;32(5):368-377. Epub 2018 Mar 8.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. Electronic address:

Myelodysplastic syndromes (MDS) are a heterogeneous group of hemopathies that exhibit physical manifestations with clinical consequences of bone marrow failure and inherent risk of progression to acute myeloid leukemia. Iron overload (IO) is common in MDS due to chronic transfusion support and disease-related alterations in iron metabolism. IO has been conclusively associated with inferior outcomes among MDS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.002DOI Listing
September 2018
25 Reads

Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.

Blood Rev 2018 09 16;32(5):387-399. Epub 2018 Mar 16.

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United States.

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the world. Patient with CLL are at particular risk for infections due to inherent disease-related immune dysfunction in addition to the effect of certain systemic therapies on the immune system. The advent of B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib has led to a practice change that utilizes these targeted agents in the treatment of CLL, either in place of chemoimmunotherapy (CIT) or in later line settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.004DOI Listing
September 2018
6 Reads
1 Citation
5.570 Impact Factor

Approach to pancytopenia: Diagnostic algorithm for clinical hematologists.

Blood Rev 2018 09 5;32(5):361-367. Epub 2018 Mar 5.

Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA; Department of Oncology, KFSHRC, Riyadh, Saudi Arabia.

Pancytopenia is a relatively common phenomenon encountered in clinical practice. The evaluation of a patient with pancytopenia requires a comprehensive approach and identifying the underlying cause can be challenging given the wide range of etiologies including drugs, autoimmune conditions, malignancies, infections, hemophagocytosis, and inheritable conditions. Recent advances in molecular hematology which include genomic profiling and next-generation sequencing have helped gain major insights into various hematological conditions and can guide diagnosing specific diseases in a shorter time at lower costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.001DOI Listing
September 2018
22 Reads

The possible role of maintenance treatment for primary central nervous system lymphoma.

Blood Rev 2018 09 11;32(5):378-386. Epub 2018 Mar 11.

Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel. Electronic address:

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor. The prognosis is poor, with high rates of relapse and disease progression after treatment. In addition, PCNSL affects a largely older population, so that a significant proportion of patients are ineligible for intensive therapies and high-dose chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.03.003DOI Listing
September 2018
1 Read

Standing up to the cardiometabolic consequences of hematological cancers.

Blood Rev 2018 09 21;32(5):349-360. Epub 2018 Feb 21.

Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC, Australia. Electronic address:

Hematological cancer survivors are highly vulnerable to cardiometabolic complications impacting long-term health status, quality of life and survival. Elevated risk of diabetes and cardiovascular disease arises not only from the effects of the cancers themselves, but also from the toxic effects of cancer therapies, and deconditioning arising from reduced physical activity levels. Regular physical activity can circumvent or reverse adverse effects on the heart, skeletal muscle, vasculature and blood cells, through a combination of systemic and molecular mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.02.005DOI Listing
September 2018
2 Reads

Bispecific antibody based therapeutics: Strengths and challenges.

Blood Rev 2018 07 20;32(4):339-347. Epub 2018 Feb 20.

Department of Medicine, Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA.

Monoclonal antibody-based targeted therapy has greatly improved treatment options for patients. However, long-term efficacy of such antibodies is limited by resistance mechanisms. New insights into the mechanisms by which tumors evade immune control have driven innovative therapeutic strategies to eliminate cancer by re-directing immune cells to tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2018.02.004DOI Listing
July 2018
4 Reads